查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1405882

女性健康市场规模、份额、趋势分析报告：按应用、按年龄、按地区、细分市场预测，2024-2030 年

Women's Health Market Size, Share & Trends Analysis Report By Application (Postmenopausal Osteoporosis, Infertility, Endometriosis & Uterine Fibroids, Menopause, PCOS), By Age, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10个工作天内

价格

女性健康市场的成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球女性健康市场规模将达到670.7亿美元，2024年至2030年复合年增长率为5.4%。

创新的新产品推出和女性健康领域强大的产品线是推动市场成长的关键因素。例如，2021 年 5 月，美国食品药物管理局核准了辉瑞与 Myovant Sciences 合作开发的 Myfenbrey，用于治疗与月经出血过多相关的子宫肌瘤。子宫内膜异位症盛行率的增加和非营利组织的支持增加预计将在预测期内推动市场成长。

例如，比尔及梅琳达盖兹基金会已承诺从 2021 年至 2030 年每年提供 2.8 亿倡议，用于支持新避孕技术和计划生育措施的开发。根据世界卫生组织 2021 年报告，全球约 10%（1.9 亿人）的育龄女孩和妇女受到子宫内膜异位症的影响。子宫内膜异位症是一种慢性疾病，会导致经痛、排便疼痛、腹胀、噁心和疲劳。 COVID-19大流行对市场产生了负面影响。各国政府为遏制 SARS-CoV-2 传播而采取的严格措施，例如保持社交距离和全部区域封锁，对治疗设施和妇科诊所产生了负面影响。

例如，低收入和中等收入国家长效和短效可逆避孕药的使用率下降。主要企业在产品开发和商业化方面的研究合作、协议和联盟等策略性倡议预计将推动市场成长。例如，2021年10月，Richter和Hikma签订了一项独家授权协议，在美国商业化Denosumab，该药物构成Xgeva和Prolia的生物相似药。此外，学名药竞争的加剧预计将在专利到期后增加价格压力并阻碍市场成长。

例如，专利到期后，Forteo的销售额从2020年到2021年下降了23%。由于优惠的报销政策、主要市场参与者的存在、支持性的政府法规、产品核准和商业化以及女性避孕器具的高使用率，2021 年全球市场将由北美主导。由于政府在妇女健康方面的支出增加，预计亚太地区在预测期内将以最快的复合年增长率成长。例如，澳洲政府宣布投资 3.33 亿美元支持卫生服务和支援。

女性健康市场报告亮点

  • 由于计划生育意识的提高和避孕技术的快速进步，避孕药具领域在 2023 年占据了全球销售额的 35.25% 以上的高市场占有率。
  • 加州大学比克斯比中心发布了报销指南，帮助医疗保健提供者为女性提供全方位的避孕药具。
  • 由于 Relugoliz 等产品的推出以及即将推出的针对子宫肌瘤女性的治疗药物 Linzagolix，预计子宫内膜异位症领域将在预测期内显着增长。
  • 按年龄划分，随着预期寿命的延长推动全球更年期人口增加，预计 50 岁以上人群在预测期内将实现 6.7% 的最快增长率。
  • 根据国际更年期协会统计，全球整体女性普遍经历闭经在45岁至55岁之间，平均发病年龄为51.5岁。

目录

第一章调查方法和范围

第 2 章执行摘要

第 3 章 女性健康市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场抑制因素分析
  • 女性健康市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章 女性保健品市场：使用量估算及趋势分析

  • 2023年及2030年技术市场占有率
  • 细分仪表板
  • 全球女性健康市场应用前景展望
  • 2018-2030 年市场规模、预测与趋势分析如下
    • 荷尔蒙不孕症
    • 避孕药
    • 停经后骨质疏鬆症
    • 子宫内膜异位症和子宫肌瘤
    • 闭经
    • 卵巢症候群（PCOS）

第五章 女性健康市场：年龄估算及趋势分析

  • 2023年及2030年治疗市场占有率
  • 细分仪表板
  • 按年龄分類的全球女性健康市场前景
  • 2018-2030 年市场规模、预测与趋势分析如下
    • 50岁以上
    • 其他的

第六章 女性健康市场：区域估算与趋势分析

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概况
  • 2018-2030年市场规模及预测趋势分析
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争分类
  • 供应商形势
    • List of key distributors and channel partners
    • Key customers
    • Key company market share analysis, 2023
    • AbbVie, Inc.
    • Bayer AG
    • Merck &Co., Inc.
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Agile Therapeutics
    • Amgen, Inc.
    • Apothecus Pharmaceutical Corp.
    • Blairex Laboratories, Inc.
    • Ferring BV
Product Code: GVR-1-68038-634-9

Women's Health Market Growth & Trends:

The global women's health market size is expected to reach USD 67.07 billion by 2030, registering a CAGR of 5.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. The introduction of innovative novel products and the presence of a strong pipeline of women's health products are prime factors driving the market growth. For instance, in May 2021, the Food & Drug Administration approved Myfembree, developed by Pfizer Inc. in collaboration with Myovant Sciences, for uterine fibroids associated with heavy menstrual bleeding. An increase in the incidence of endometriosis and a rise in support from non-profit organizations are expected to fuel the market growth over the forecast period.

For instance, the Bill & Melinda Gates Foundation pledged USD 280 million every year from 2021 to 2030 for the development of new contraceptive technologies and to support family planning initiatives. According to the WHO report 2021, globally, around 10% (190 million) of reproductive-age girls and women are affected by endometriosis. It is a chronic disease related to severe pain during periods, bowel movements and/or urination, abdominal bloating, nausea, fatigue, etc. The COVID-19 pandemic had a negative impact on the market. Strict measures undertaken by governments to control the spread of the SARS-CoV-2, such as social distancing and community-wide lockdowns, have had a detrimental impact on treatment facilities & gynecological clinics.

For instance, in low- and middle-income countries there has been a decline in the usage of long- and short-acting reversible contraceptives. Strategic initiatives undertaken by key players, such as collaborations, agreements, and partnerships, for the development and commercialization of products are anticipated to drive market growth. For instance, in October 2021, Richter and Hikma signed an exclusive licensing agreement to commercialize denosumab, comprising biosimilar of Xgeva and Prolia in the U.S. Moreover, the growing competition from generic drugs increases the pricing pressure after patent expiration, which is anticipated to impede market growth.

For instance, after the patent expiry, the revenue of Forteo declined by 23% between 2020 and 2021. North America dominated the global market in 2021 owing to favorable reimbursement policies, the presence of key market players, supportive government regulations, approval & commercialization of products, and high usage of contraceptives among women. The Asia Pacific region is expected to grow at the fastest CAGR during the forecast period due to rising government spending on women's health. For instance, the Australian Government announced an investment of USD 333 million to support health services and support.

Women's Health Market Report Highlights:

  • The contraceptives segment held the highest market share of more than 35.25% of the global revenue in 2023 due to increased awareness about family planning and rapid technological advancements in contraception
  • The University of California Bixby Center released a reimbursement guide to help health providers offer women a full range of contraceptives
  • The endometriosis segment is expected to witness significant growth over the forecast period due to the launch of products, such as Relugoliz and the impending launch of Linzagolix for the treatment of women with uterine fibroids
  • Based on age, the 50 years and above segment is expected to register the fastest growth rate of 6.7% over the forecast period as an increase in life expectancy is boosting the overall menopausal population across the globe
  • According to the International Menopause Society, globally, women aged between 45 and 55 years typically experience menopause, with the average age of onset at 51.5 years

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Application
    • 1.2.2. Age
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for Primary Interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for Primary Interviews in Latin America
      • 1.4.5.5. Data for Primary Interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Application outlook
    • 2.2.2. Age outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Women's Health Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising incidence of target diseases
      • 3.2.1.2. Increasing initiatives by government and various organizations
      • 3.2.1.3. Rising publicly funded family planning services
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Patent expiry of major drugs
      • 3.2.2.2. Lawsuits related to products
      • 3.2.2.3. Adverse effects associated with use of contraceptive drugs and devices
  • 3.3. Women's Health Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic Landscape

Chapter 4. Women's Health Market: Application Estimates & Trend Analysis

  • 4.1. Technology Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Women's Health Market by Application Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Hormonal infertility
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Contraceptives
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Postmenopausal osteoporosis
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Endometriosis & uterine fibroids
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Menopause
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.6. Polycystic ovary syndrome (PCOS)
      • 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Women's Health Market: Age Estimates & Trend Analysis

  • 5.1. Treatment Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Women's Health Market by Age Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. 50 years and above
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2. Postmenopausal osteoporosis
      • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3. Endometriosis & uterine fibroids
      • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.4. Menopause
      • 5.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.5. Others
      • 5.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Others
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Women's Health Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2023 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Norway
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/reimbursement structure
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.8. Denmark
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/reimbursement structure
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/reimbursement structure
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/reimbursement structure
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.2. Mexico
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.3. Argentina
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework/reimbursement structure
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Regulatory framework/reimbursement structure
      • 6.9.1.3. Competitive scenario
      • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/reimbursement structure
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/reimbursement structure
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/reimbursement structure
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. AbbVie, Inc.
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Bayer AG
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Merck & Co., Inc.
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Pfizer, Inc.
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Teva Pharmaceutical Industries Ltd.
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Agile Therapeutics
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Amgen, Inc.
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. Apothecus Pharmaceutical Corp.
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Blairex Laboratories, Inc.
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. Ferring B.V.
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Product benchmarking
      • 7.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America women's health market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America women's health market, by application, 2018 - 2030 (USD Million)
  • Table 4 North America women's health market, by age, 2018 - 2030 (USD Million)
  • Table 5 U.S. women's health market, by application, 2018 - 2030 (USD Million)
  • Table 6 U.S. women's health market, by age, 2018 - 2030 (USD Million)
  • Table 7 Canada women's health market, by application, 2018 - 2030 (USD Million)
  • Table 8 Canada women's health market, by age, 2018 - 2030 (USD Million)
  • Table 9 Europe women's health market, by region, 2018 - 2030 (USD Million)
  • Table 10 Europe women's health market, by application, 2018 - 2030 (USD Million)
  • Table 11 Europe women's health market, by age, 2018 - 2030 (USD Million)
  • Table 12 Germany women's health market, by application, 2018 - 2030 (USD Million)
  • Table 13 Germany women's health market, by age, 2018 - 2030 (USD Million)
  • Table 14 UK women's health market, by application, 2018 - 2030 (USD Million)
  • Table 15 UK women's health market, by age, 2018 - 2030 (USD Million)
  • Table 16 France women's health market, by application, 2018 - 2030 (USD Million)
  • Table 17 France women's health market, by age, 2018 - 2030 (USD Million)
  • Table 18 Italy women's health market, by application, 2018 - 2030 (USD Million)
  • Table 19 Italy women's health market, by age, 2018 - 2030 (USD Million)
  • Table 20 Spain women's health market, by application, 2018 - 2030 (USD Million)
  • Table 21 Spain women's health market, by age, 2018 - 2030 (USD Million)
  • Table 22 Denmark women's health market, by application, 2018 - 2030 (USD Million)
  • Table 23 Denmark women's health market, by age, 2018 - 2030 (USD Million)
  • Table 24 Sweden women's health market, by application, 2018 - 2030 (USD Million)
  • Table 25 Sweden women's health market, by age, 2018 - 2030 (USD Million)
  • Table 26 Norway women's health market, by application, 2018 - 2030 (USD Million)
  • Table 27 Norway women's health market, by age, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific women's health market, by region, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific women's health market, by application, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific women's health market, by age, 2018 - 2030 (USD Million)
  • Table 31 China women's health market, by application, 2018 - 2030 (USD Million)
  • Table 32 China women's health market, by age, 2018 - 2030 (USD Million)
  • Table 33 Japan women's health market, by application, 2018 - 2030 (USD Million)
  • Table 34 Japan women's health market, by age, 2018 - 2030 (USD Million)
  • Table 35 India women's health market, by application, 2018 - 2030 (USD Million)
  • Table 36 India women's health market, by age, 2018 - 2030 (USD Million)
  • Table 37 South Korea women's health market, by application, 2018 - 2030 (USD Million)
  • Table 38 South Korea women's health market, by age, 2018 - 2030 (USD Million)
  • Table 39 Australia women's health market, by application, 2018 - 2030 (USD Million)
  • Table 40 Australia women's health market, by age, 2018 - 2030 (USD Million)
  • Table 41 Thailand women's health market, by application, 2018 - 2030 (USD Million)
  • Table 42 Thailand women's health market, by age, 2018 - 2030 (USD Million)
  • Table 43 Latin America women's health market, by region, 2018 - 2030 (USD Million)
  • Table 44 Latin America women's health market, by age, 2018 - 2030 (USD Million)
  • Table 45 Latin America women's health market, by application, 2018 - 2030 (USD Million)
  • Table 46 Brazil women's health market, by application, 2018 - 2030 (USD Million)
  • Table 47 Brazil women's health market, by age, 2018 - 2030 (USD Million)
  • Table 48 Mexico women's health market, by application, 2018 - 2030 (USD Million)
  • Table 49 Mexico women's health market, by age, 2018 - 2030 (USD Million)
  • Table 50 Argentina women's health market, by application, 2018 - 2030 (USD Million)
  • Table 51 Argentina women's health market, by age, 2018 - 2030 (USD Million)
  • Table 52 MEA women's health market, by region, 2018 - 2030 (USD Million)
  • Table 53 MEA women's health market, by application, 2018 - 2030 (USD Million)
  • Table 54 MEA women's health market, by age, 2018 - 2030 (USD Million)
  • Table 55 South Africa women's health market, by application, 2018 - 2030 (USD Million)
  • Table 56 South Africa women's health market, by age, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia women's health market, by application, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia women's health market, by age, 2018 - 2030 (USD Million)
  • Table 59 UAE women's health market, by application, 2018 - 2030 (USD Million)
  • Table 60 UAE women's health market, by age, 2018 - 2030 (USD Million)
  • Table 61 Kuwait women's health market, by application, 2018 - 2030 (USD Million)
  • Table 62 Kuwait women's health market, by age, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary Interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Women's health market: market outlook
  • Fig. 14 Women's Health Competitive Insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Women's health market driver impact
  • Fig. 20 Women's health market restraint impact
  • Fig. 21 Women's Health Market Strategic Initiatives Analysis
  • Fig. 22 Women's health market: Application movement analysis
  • Fig. 23 Women's health market: Application outlook and key takeaways
  • Fig. 24 Hormonal infertility market estimates and forecast, 2018 - 2030
  • Fig. 25 Contraceptives estimates and forecast, 2018 - 2030
  • Fig. 26 Postmenopausal osteoporosis market estimates and forecast, 2018 - 2030
  • Fig. 27 Endometriosis & uterine fibroids estimates and forecast, 2018 - 2030
  • Fig. 28 Menopause market estimates and forecast, 2018 - 2030
  • Fig. 29 Polycystic ovary syndrome (PCOS) estimates and forecast, 2018 - 2030
  • Fig. 30 Women's Health Market: Age Movement Analysis
  • Fig. 31 Women's health market: Age outlook and key takeaways
  • Fig. 32 50 years and above market estimates and forecasts, 2018 - 2030
  • Fig. 33 Postmenopausal osteoporosis market estimates and forecasts,2018 - 2030
  • Fig. 34 Endometriosis & uterine fibroids market estimates and forecasts,2018 - 2030
  • Fig. 35 Menopause market estimates and forecasts,2018 - 2030
  • Fig. 36 Others market estimates and forecasts,2018 - 2030
  • Fig. 37 Others market estimates and forecasts,2018 - 2030
  • Fig. 38 Global women's health market: Regional movement analysis
  • Fig. 39 Global women's health market: Regional outlook and key takeaways
  • Fig. 40 Global women's health market share and leading players
  • Fig. 41 North America market share and leading players
  • Fig. 42 Europe market share and leading players
  • Fig. 43 Asia Pacific market share and leading players
  • Fig. 44 Latin America market share and leading players
  • Fig. 45 Middle East & Africa market share and leading players
  • Fig. 46 North America: SWOT
  • Fig. 47 Europe SWOT
  • Fig. 48 Asia Pacific SWOT
  • Fig. 49 Latin America SWOT
  • Fig. 50 MEA SWOT
  • Fig. 51 North America, by country
  • Fig. 52 North America
  • Fig. 53 North America market estimates and forecasts, 2018 - 2030
  • Fig. 54 U.S.
  • Fig. 55 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 56 Canada
  • Fig. 57 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 58 Europe
  • Fig. 59 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 60 UK
  • Fig. 61 UK market estimates and forecasts, 2018 - 2030
  • Fig. 62 Germany
  • Fig. 63 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 64 France
  • Fig. 65 France market estimates and forecasts, 2018 - 2030
  • Fig. 66 Italy
  • Fig. 67 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 68 Spain
  • Fig. 69 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 70 Denmark
  • Fig. 71 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 72 Sweden
  • Fig. 73 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 74 Norway
  • Fig. 75 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 76 Asia Pacific
  • Fig. 77 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 78 China
  • Fig. 79 China market estimates and forecasts, 2018 - 2030
  • Fig. 80 Japan
  • Fig. 81 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 82 India
  • Fig. 83 India market estimates and forecasts, 2018 - 2030
  • Fig. 84 Thailand
  • Fig. 85 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 86 South Korea
  • Fig. 87 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 88 Australia
  • Fig. 89 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 90 Latin America
  • Fig. 91 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 92 Brazil
  • Fig. 93 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 94 Mexico
  • Fig. 95 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 96 Argentina
  • Fig. 97 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 98 Middle East and Africa
  • Fig. 99 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 100 South Africa
  • Fig. 101 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 102 Saudi Arabia
  • Fig. 103 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 104 UAE
  • Fig. 105 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 106 Kuwait
  • Fig. 107 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 108 Market share of key market players- Women's health market